Overview

A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects

Status:
Completed

Trial end date:
2018-05-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect of clopidogrel on the pharmacokinetics of selexipag and its active metabolite (ACT-333679) in healthy male adults (by determining the blood concentrations of selexipag and its metabolite). Also, the safety of selexipag when administered alone or with clopidogrel will be assessed.

Phase:

Phase 1

Details

Lead Sponsor:

Actelion

Treatments:

Clopidogrel
Selexipag
Ticlopidine